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Abstract Low vitamin D status and obesity have concomi-
tantly reached epidemic levels worldwide. Up to now the di-
rection of the association between low vitamin D status and
obesity, the exact mechanisms responsible for this association
and the clinical usefulness to increase vitamin D status for
reducing adiposity still warrant further evaluation. The aim
of the present review was to examine the current evidence
linking low vitamin D status and obesity in relation to the role
of the nutritionist. On the one side, considering obesity as a
causal factor, low sun exposure in obese individuals due to
their sedentary lifestyle and less outdoor activity, vitamin D
sequestration in adipose tissue, and volumetric dilution of
ingested or cutaneously synthesized vitamin D3 in the large
fat mass of obese patients, might represent some of the factors
playing a major role in the pathogenesis of the low vitamin D
status. On the other side, the expression of both vitamin D3
receptors and enzymes responsible for vitamin D3 metabolism
in adipocytes depicted a role for the low vitamin D status per
se in the development of obesity by modulating adipocyte
differentiation and lipid metabolism. Nutritionists need to ac-
curately address the aspects influencing the low vitamin D
status in obesity and the vitamin D supplementation in obese
individuals.
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1 Text
Low vitamin D status and obesity have concomitantly reached
epidemic levels worldwide and research linking these two
public health issues has grown extensively over the last num-
ber of years. The modern and westernised lifestyles is consid-
ered the major responsible on the one side for increasing obe-
sity, on the other side for decreasing the vitamin D status.
Although limited by the cross-sectional design of the vast
majority of the investigations, a number of clinical studies
Silvia Savastano and Luigi Barrea equally contributed to this work.
* Annamaria Colao
colao@unina.it
Silvia Savastano
sisavast@unina.it
Luigi Barrea
luigi.barrea@unina.it
Maria Cristina Savanelli
cristysav@hotmail.com
Francesca Nappi
dott.ssa.nappi@gmail.com
Carolina Di Somma
cdisomma@unina.it
Francesco Orio
francescoorio@virgilio.it
1 Dipartimento di Medicina Clinica e Chirurgia, Unit of
Endocrinology, Federico II UniversityMedical School of Naples, Via
Sergio Pansini 5, 80131 Naples, Italy
2 I.O.S. & COLEMAN Srl, 80011 Acerra, Naples, Italy
3 IRCCS SDN, Napoli Via Gianturco 113, 80143 Naples, Italy
4 Department of Sports Science and Wellness, BParthenope^
University of Naples, Naples, Italy
Rev Endocr Metab Disord
DOI 10.1007/s11154-017-9410-7
support the role of obesity as a causal risk factor for the de-
velopment of the low vitamin D status [1]. Indeed, different
large epidemiological studies, including the National Health
and Nutrition Examination Survey (NHANES) III [2] and the
Framingham study [3], have shown increasing prevalence of
low vitamin D status with greater body mass index (BMI),
also independently of variation in physical activity or vitamin
D intake. In particular, it has been calculated that each unit
increase of BMI was associated with a 1.15% decrease of 25-
hydroxyvitamin D3 [25(OH)D3] levels [4]. In addition, circu-
lating levels of 25(OH)D3 increased after weight loss in the
obese individuals through lifestyle interventions without vita-
min D supplementation [5]. However, clinical trials investi-
gating the effects of vitamin D supplementation on body
weight have not provided consistent data on the possible
favourable effects of vitamin D on weight loss [6, 7]. The
association between the low vitamin D status and obesity
has been analysed in a recent meta-analysis of 15 studies
which included 3867 subjects with obesity and 9342 health
subjects [8]. In this study, serum 25(OH)D3 levels >20 ng/mL
(>50 nmol/L) were considered adequate according to the
Institute of Medicine (IOM), or >30 ng/mL (≥75 nmol/L)
according to the Endocrinology Society [9]. On the basis of
these classifications, a positive association between low vita-
min D status and high risk of obesity incidence was reported,
irrespective of geographical areas. In particular, the prevalence
of vitamin D deficiencywas positively associated with obesity
in both Asians and European-Americans, with odd ratios
(95% CI) of 3.70 (1.98–6.90) and 3.09 (1.89–5.04), respec-
tively. Nevertheless, it is not clear whether obesity plays a
causal role in the development of the low vitamin D status
or, alternatively, the low vitamin D status is involved in the
development of obesity, as well as of other metabolism-related
morbidities [10]. Indeed, the low vitamin D status is likely to
contribute per se to the development of overweight/obesity
[11] and different genomic and non-genomic mechanisms
exerted by vitamin D3 have been proposed to have a causative
role in obesity [12, 13]. A large study based on 42.024 partic-
ipants of European descent suggested a causal relation for
higher BMI on low serum 25(OH)D3 status, while the effect
of serum 25(OH)D3 on BMI was absent or minimal [4]. In
addition, data from three large cohorts, based on repeated
measures of anthropometry as well as information on several
potential confounders, such as season, geographic latitude,
cloudiness and smog, limited sun exposure and outdoor phys-
ical activity or low vitamin D intake, evidenced that any caus-
al relationship between 25 (OH)D3 and annual changes in
body weight was either not present or small [14]. Thus, up
to now the nature of the association between low vitamin D
status and obesity is still debatable, the exact mechanisms
responsible for this association remain unclear, and the clinical
usefulness to increase vitamin D status for reducing adiposity
still warrants further evaluation.
Aim of this paper was to provide at-a-glance overview of
the possible bi-directional mechanisms linking the low vita-
min D status and obesity and the potential involvement of a
nutritional approach as a rational basis to help clinicians de-
cide the appropriate vitamin D replacement doses for obese
individuals.
2 Obesity as a causal factor of the low vitamin D
status
2.1 Decreased sun exposure
Sunlight exposure provides in humans for more than 90% of
the production of vitamin D [15]. In particular, solar ultraviolet
(UV)-B radiation (UVB; wavelengths of 290 to 315 nm) stim-
ulates the synthesis of vitamin D3 from 7-dehydrocholesterol,
the vitamin D precursor, in the epidermis of the skin [16].
Obese individuals have a larger body surface area that is avail-
able for endogenous synthesis of vitaminD [17]. Nevertheless,
obese individuals often conduct a sedentary lifestyle, partake
in less outdoor activity, and cover-up more when outdoors
compared with their lean or normal-weight counterparts, thus
limiting the endogenous production of cholecalciferol in the
skin [4, 18–20]. While the content in the skin of 7-
dehydrocholesterol was not significantly different between
obese and non-obese subjects, it has been calculated that the
increase in serum vitamin D3 concentrations was about one
half in the obese than in the non-obese subjects 24 h after the
exposure, despite the greater body surface area in the formers
[21]. However, in this study the Authors did not provide any
data on the amount and location of vitamin D3 storage in fat
tissue and the mechanisms that control the deposition and re-
lease of vitamin D3.
A growing body of evidence proved that air pollution con-
stitutes an independent risk factor in the pathogenesis of both
obesity and low vitamin D status, in combination with un-
healthy diet and lifestyle. The possible contribution of air pol-
lution on the relationship between low vitamin D status and
obesity has been treated elsewhere in this issue [22].
2.2 Sequestration in adipose tissue
Adipose tissue is a major repository of vitamin D3 in the body
[23–25]. Thus, it has also been suggested that the metabolic
clearance of vitamin D3 may increase in obesity, possibly with
enhanced uptake by adipose tissue. Nevertheless, the amount
and location of vitamin D3 storage in fat tissue and the mech-
anisms that control the deposition and release of vitamin D3
are still unknown. Adipose tissue could function as a vitamin
D buffering system that prevents uncontrolled synthesis of
25(OH)D3 in the liver [25]. The slow release of vitamin D3
from adipose tissue under fasting conditions could represent
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the rate limiting step to protect against the potential toxicity of
excess amounts of the vitamin [23]. However, large accrual in
adipose tissue depot implies that vitamin D3 could not be
appropriately released into the general circulation to support
serum 25(OH)D3 concentrations. The adipose tissue seques-
tration was originally suggested by Wortsman et al. [21], who
found that obesity-associated vitamin D insufficiency was
likely due the decreased bioavailability of cholecalciferol (vi-
tamin D3) from cutaneous and dietary sources because of its
deposition in body fat compartments. According with this
hypothesis, Malmberg P et al. [26], by using imaging mass
spectrometry techniques, demonstrated that vitamin D3 and its
metabolites 25(OH)D3, and 1,25-dihydroxyvitamin D3
[1α,25(OH)2D3] were located in adipocyte lipid droplets, al-
though the vitamin D3 concentration is not uniform through-
out various fat depots. Heaney RP. et al. have reported as
about 17% of orally-administered vitamin D3 dose was stored
in adipose tissue and the rest was consumed or metabolized
[27]. However, other factors, such as volumetric dilution, vi-
tamin D3 intake, and diet composition, may also contribute to
low vitamin D status in obese subjects. Thus, more studies are
needed to characterize the distribution and metabolism of vi-
tamin D3 in different fat compartments.
2.3 Volumetric dilution
The sequestration and the inappropriate storage of vitamin D3
in adipose tissue did not explain the low vitamin D status of
obesity, as once the values in obesity are adjusted for body
size, there is no longer a difference in 25(OH)D3 concentra-
tions between normal and obese individuals. Most recently,
convincing data suggest that the low vitamin D status of obe-
sity could be simply the consequence of the volumetric dilu-
tion of ingested or cutaneously synthesized vitamin D3 in the
large fat mass of obese patients. Drincic et al. [28] reported
that the volumetric dilution accounted for essentially all the
variability in serum 25(OH)D3 concentration attributable to
obesity. A subsequent article from the same Authors charac-
terized the pharmacokinetics of the 25(OH)D3 response to 3
different doses of vitamin D3 in a group of obese subjects to
quantify the dose needed to raise 25(OH)D3 level according to
body weight. On this basis, the Authors provided a weight-
based equation to estimate the amount of vitamin D3 needed to
raise serum 25(OH)D3 by any desired amount [29].
2.4 Parathyroid hormone (PTH)
A low vitamin D status is known to induce secondary hyper-
parathyroidism that causes the overflow of calcium into adi-
pocytes, thereby increasing lipogenesis [30]. Increased intra-
cellular calcium in adipocytes increases the expression of fatty
acid synthase, a key regulatory enzyme in the deposition of
lipids, and decreases lipolysis [31]. Alternatively, the presence
of a negative feedback from elevated 1α,25(OH)2D3 and para-
thyroid hormone (PTH) levels on hepatic synthesis of
25(OH)D3 could be postulated, although the mechanism by
which the feedback regulation of the 25(OH)D3 production
occurs has not been established [32]. In this context, it has
been reported that normalization of 25(OH)D3 levels in sub-
jects with low vitamin D could participate to prevent weight
gain by reducing the 1α,25(OH)2D3 production, likely
through lowering PTH levels [33].
2.5 Leptin
The satiety hormone leptin, secreted by adipocytes, is posi-
tively correlated with the amount of body fat and reflects
energy status [34]. Leptin exerts an autocrine–paracrine lipo-
lytic effect on adipocytes by interacting with vitamin D recep-
tor (VDR) to control lipid metabolism through inhibition of
lipogenesis and stimulation of lipolysis [35]. Recently, it has
been found that 1α,25(OH)2D3 directly stimulated mRNA
expression and secretion of leptin in mouse adipose tissue
cultures [36]. Thus, the vitamin D3 depletion might increase
appetite and lead to obesity by directly regulating leptin ex-
pression [37]. However, the exact in vivo effect of
1α,25(OH)2D3 on leptin expression in humans needs further
investigation.
2.6 Non-alcoholic fatty liver disease
Hepatic steatosis in obese subjects may result in low synthesis
of 25(OH)D3 by the liver. Non-alcoholic fatty liver disease
(NAFLD) includes a spectrum of disorders of increasing se-
verity from simple fatty liver, non-alcoholic steatohepatitis,
cirrhosis, to hepatocellular carcinoma [38]. NAFLD is com-
monly found among obese individuals, mainly linked to the
damage caused by fatty infiltration, oxidative stress and im-
paired cellular regeneration associated with insulin resistance
(IR) and obesity [39]. In this, NAFLD has been defined as the
hepatic manifestation of metabolic syndrome [40]. On the
other hand, the association between vitamin D levels and
NAFLD has been increasingly recognized, with an inverse
association with the histologic severity of NAFLD [41]. In
particular, a recent meta-analysis reported that low vitamin
D status were 26% more common in NAFLD patients than
in healthy persons [42]. Although several researches indicated
the existence of an independent association between the low
vitamin D status and NAFLD, this association could be a
consequence of shared risk factors for NAFLD and obesity,
such as a sedentary lifestyle or unhealthy dietary pattern, and
the loss of vitamin D hydroxylation capacity by the liver has
not demonstrated as the cause of hypovitaminosis D in
NAFLD patients.
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2.7 Insulin resistance
The low vitamin D status is a common problem associated
with obesity and IR. In particular, the link between the low
vitamin D status and obesity seems to have negative conse-
quences on IR and glucose homeostasis [43]. The negative
associations between low vitamin D status and IR have been
reported in cross-sectional [44–46], prospective [47], and sup-
plementation studies [48–50]. The underlying mechanisms by
which vitamin D decreases the risk of IR have not yet eluci-
dated. Several pathways have been suggested to be involved.
Of interest, the negative association between 25(OH)D3 levels
and fasting insulin concentrations or IR has been reported also
independently of BMI [51]. VitaminVitamin D deficiency has
been reported to be associated with an increase in PTH, which
in turn is associated with decreased insulin sensitivity [52]. In
addition, vitamin D regulates calcium homeostasis and has a
role in maintaining adequate intracellular levels of calcium for
intracellular process in insulin-responsive tissues, such as
muscle cells [53]. Furthermore, VDR are found in pancreatic
β-cells, and vitamin D is involved in some of the biological
activities of insulin, including physiological insulin secretion,
stimulation of the expression of insulin receptors, and increas-
ing insulin responsiveness for glucose transport [54].
3 Low vitamin D status as causal factor of obesity
3.1 Vitamin D/VDR system
VDR is a nuclear steroid hormone receptors which binds to
vitamin D3 with high affinity and specificity [55, 56]. Recent
research has demonstrated that adipose tissue expressed VDR
and enzymes responsible for vitamin D3 metabolism, includ-
ing the 1α-hydroxylase, locally converting 25(OH)D3 to
1α,25(OH)2D3 [13]. Thus, adipocytes could be involved in
the local synthesis as well as the degradation of biologically
active vitamin D3 and then, the adipose tissue may be a direct
target of vitamin D [13]. Vitamin D3 modulation of adipocyte
growth and metabolism could involve both genomic and non-
genomic actions [57, 58]. In differentiated 3 T3-L1 cells, low
doses of vitamin D3 inhibited apoptosis, whereas high doses
stimulated apoptosis [59]. Although contradicting results were
obtained regarding the effect of vitamin D3 on adipogenesis,
many studies supported the involvement of vitamin D/VDR
system in modulating adipocyte lipid metabolism [60]. In par-
ticular, vitamin D3 seems to play a central role in adipocyte
metabolism via the inhibition of adipogenesis, independently
of PTH [61, 62].
VDR is expressed in the earliest stages of adipocyte differ-
entiation, but its expression decreases along with the progress
of differentiation. In the presence of vitamin D3, the VDR
blocks the differentiation of pre-adipocytes by down-
regulating of a number of transcriptional regulators and func-
tional proteins exerting a key role in adipogenesis, such as
PPAR-γ, lipoprotein lipase, protein aP2, a carrier of fatty acids
necessary for lipolysis, CCAAT/enhancer-binding protein
(C/EBP) and sterol-regulatory element binding protein-1
(SREBP-1) [63]. Therefore, lower vitamin D3 levels could
increase the differentiation of preadipocytes to mature adipo-
cytes. Mature adipocytes do not express VDR. This suggests
that vitamin D3 can affect differentiation if introduced early in
the differentiation stage [63, 64]. VDR konckout mice have a
lean phenotype and were resistant to diet-induced obesity [61,
65] and also, accumuled less fat with age and high-fat diet
[66]. In primary human tissue, vitamin D3 promoted differen-
tiation of committed subcutaneous preadipocytes through in-
creased expression of some adipogenic markers and lipid fill-
ing, suggesting that the local metabolism of vitamin D3 in
adipose tissue may regulate human adipose tissue growth
and support the healthy remodelling of human adipose tissue
[37]. Also, in the presence of vitamin D3, mesenchymal cells,
derived from human adipose tissue, differentiate in adipocytes
with an enhanced lipid accumulation and increased expression
of adipogenic marker genes (FASN, FABP4, and PPARγ)
[67]. In addition, in human subcutaneous adipocyte, vitamin
D3 modulated a pattern of adipocyte gene expression of hu-
man subcutaneous adipocyte which inhibited adipocyte apo-
ptosis and favored adipocyte proliferation [68]. Of interest, the
function of VDR in adipose tissue may be gender-specific, as
the adipocyte VDR signalling has been reported to affect body
weight and fat mass in females but not in males [66]. Recent
finding has shown a positive association between VDR poly-
morphisms and adiposity [69]. In particular, VDR gene vari-
ants with polymorphisms on the 3’UTR region, a site regulat-
ing VDR gene expression, appeared to suppress the anti-
adipogenic effect of vitamin D3 and to play a role in adiposity
phenotypes [69].
3.2 1α,25(OH)2 vitamin D3
Besides vitamin D3, also adipose tissue 1α,25(OH)2D3 is able
to regulate differently the adipogenesis during the differentia-
tion process. Of interest, adipose tissue 1α-hydroxylase is not
regulated by dietary calcium and vitamin D3 like renal 1α-
hydroxylase, and other different factors, including phospho-
rus, PTH, calcitonin, estradiol, pro-inflammatory cytokines,
phytoestrogens have been proposed as regulatory agents
[35]. Previous evidence indicated that 1α,25(OH)2D3 in-
creased intracellular calcium level and subsequently fatty acid
synthase activity. Furthermore, 1α,25(OH)2D3 exerted an in-
hibitory effect on adipocyte basal lipolysis in human adipo-
cytes culture [70]. The antiadipogenic effect of 1α,25(OH)2D3
is exerted during preadipocyte differentiation by inhibiting the
mRNA expression and phosphorylation of extracellular regu-
lated kinase (ERK), one of the mitogen-activated protein
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kinase (MAPK) signalling and through the maintenance of the
WNT/b-catenin pathway, which are normally down-regulated
during adipogenesis. However, while low doses of
1α,25(OH)2D3 inhibit apoptosis in differentiated 3 T3-L1
cells, high doses stimulate apoptosis through the activation
of the Ca2+/calpain-dependent caspase-12 [71]. Of interest,
the expression of vitamin D-metabolizing enzymes is different
between lean and obese women [72].
3.3 Vitamin D and inflammatory adipokines
Vitamin D metabolites also influence adipokine production
and secretion by adipocytes [13]. Several studies demonstrat-
ed a negative correlation between vitamin D and leptin or
resistin, and a positive association with adiponectin [73–75].
Vitamin D3 also plays a central role in modulating the inflam-
matory response in adipose tissue [35]. In obesity, adipose
tissue is hypertrophic resulting in blood flow imbalance lead-
ing to hypoxia, inflammation, and macrophage infiltration. In
addition, the increase in the secretion of interleukins 6 and 8
(IL-6, IL-8), resistin, tumor necrosis factor-alpha (TNF-α) and
monocyte chemoattractant (MCP1), and a reduced secretion
of adiponectin, are characteristics in hypertrophied adipocytes
[76, 77]. Evidence in vitro demonstrated that vitamin D3
exerted an anti-inflammatory action on adipocytes by reduc-
ing chemokine and cytokine release by adipocytes and the
chemotaxis of monocytes [35]. These anti-inflammatory ef-
fects of vitamin D3 seem mediated by the inhibition of the
NFkB and MAPK signalling pathways [35].
3.4 Vitamin D and Bwinter response^
It has also been suggested that accrual in adipose tissue could
result from an excessive adaptive Bwinter response^.
According to this hypothesis, the fall in vitamin D skin syn-
thesis in winter entails an increase in body size by the accu-
mulation of fat mass, which reduces heat conductance to the
environment, and the induction of a winter metabolism, which
increases thermogenic capacity, as result of an anomalous ad-
aptation to a cold climate [78].
In conclusion, the strong scientific evidence for the se-
questration [21] and volumetric dilution [28] hypotheses,
and more importantly, a lack of contradictory evidence, sug-
gest that both mechanisms are the most probable, either
independently or in combination, to explain the low vitamin
D status widely reported in obesity. Unravelling the mecha-
nisms underlying the low vitamin D status in subjects with
obesity has important therapeutic implications both in decid-
ing on appropriate vitamin D3 replacement doses for obese
individuals and in evaluating potential effects of treatment of
vitamin D3 inadequacy.
4 Role of nutritionist in obese patients with low
vitamin D status
4.1 Vitamin D and evaluation of body composition
Fat accumulation plays a major role in the development of the
low vitamin D status compared to other body components,
such as free fat mass. Therefore, estimating the fat accumula-
tion could be clinically relevant to identify individuals with
high risk of low vitamin D status. Nevertheless, in the vast
majority of clinical studies evaluating the association between
vitamin D status and obesity, obesity has been defined only on
the basis of BMI rather than by using a direct estimate of body
fat mass. In fact, it is well known that BMI is only a measure
of the total adiposity, without discriminating body fat amount
and distribution [79], and fails to account for differences in
race, gender and age [80]. Waist circumference (WC) is con-
sidered a good marker of abdominal fat accumulation [81]. A
number of studies evaluated the relationship between vitamin
D3 and WC to better highlights the relationship between ab-
dominal adiposity and serum vitamin D3 concentration.
Rodríguez-Rodríguez et al. [82] evidenced thatWC in women
with low vitamin D3 levels was significantly larger than in that
in their counterparts with higher vitamin D3 (86.2 ± 9.3 cm vs
79.4 ± 3.4 cm; p < 0.05). It has been calculated that a reduction
of 0.29 nmol/L in serum vitamin D for every 1 cm increase in
WC (p = 0.01) [83]. However, both BMI and WC are weaker
anthropometric measurements of adiposity than direct mea-
sures of adiposity.
Although it is not considered a Bgold standard^,
biompedeance analysis (BIA) is a validated method providing
a useful alternative for measuring body fat in clinical practice,
especially to track changes in fat mass along the time [84–86].
In this regard, Looker AC examined the relationship between
serum 25(OH)D3 and percent body fat calculated from BIA in
a large sample of white and black women from the third
National Health and Nutrition Examination Survey
(NHANES III, 1988–1994) [2]. This Author found that the
serum 25(OH)D3-% body fat relationship in women varied
both by race and age (stronger in whites than blacks and in
younger than older persons). Very recently, the relationship
between vitamin D status, body composition, and cardiovas-
cular risks has been characterized in Asian population living in
Singapore, a sunny tropical region, by measuring by the body
fat percentage using different techniques, including BIA [87].
In this study, 42.1% of participants were at risk of vitamin D
deficiency (<20 ng/mL), with females (54.5%) showing a
higher prevalence of vitamin D deficiency than males
(30.5%), likely due to a higher body fat percentage in females
than males. Of interest, the difference of vitamin D deficiency
between males and females did not persist after adjusting for
body fat percentage, suggesting that body fat may be one of
the predominant risk factors for vitamin D deficiency.
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Anthropometric measures and BIA, however, do not al-
low to discriminate between the adipose tissue located in the
abdominal cavity and retroperitoneal area, which is com-
monly known as intra-abdominal or visceral adipose tissue
(VAT), and the adipose tissue stored subcutaneously (SAT),
threatening to underestimated the association between vita-
min D status and overall adiposity. The dual-energy x-ray
absorptiometry (DEXA), computed tomography (CT) and
magnetic resonance imaging (MRI) are considered the gold
standard imaging modality for the precise estimation of the
location and amount of adipose tissue in various body re-
gions [88]. However, DEXA, CT and MRI imaging are im-
practical for screening general population, in that they expo-
sure to radiation and require expensive and specialized
equipment. Some studies have examined the relation be-
tween vitamin D status and adiposity by using volumetric
quantification of SAT and VAT compartments. In particular,
Young KA et al. [89] showed that a low vitamin D status
was associated with higher SAT as well as higher VAT,
suggesting that vitamin D3 levels were associated with both
types of adipose tissue. In addition, other investigators re-
ported a strong negative correlation between 25(OH)D3 con-
centrations and CT measures of VAT in obese adolescents
[90], and with VAT and SAT in young women [91].
Likewise, the third-generation Framingham Heart Study ev-
idenced that higher adiposity were correlated with lower
25(OH)D3 across different categories of BMI, and the prev-
alence of vitamin D deficiency (25[OH] D < 20 ng/mL) was
threefold higher in those with high SAT and high VAT than
in those with low SAT and low VAT, measured by multide-
tector CT [3]. Moreover, Sulistyoningrum DC et al. [92]
reported that VAT, may have a distinct role in determining
plasma 25(OH)D3 concentrations, compared to other adipose
tissue compartments. Finally, Rosenblum JL et al. investigat-
ed in a study double-blind, placebo-controlled trials conduct-
ed in 171 participants for 16-week for evaluated the effect of
calcium and vitamin D supplementation on weight loss and
reduction of VAT in overweight and obese adults. After
16 week, in the supplementation group, the reduction of
VAT was significantly greater than in the control group, after
control for baseline VAT. These results suggested that calci-
um and/or vitamin D supplementation contributes to a ben-
eficial reduction of VAT [93].
4.2 Vitamin D and nutrition
There is universal concern in terms of intake vitamin D,
although the concern about vitamin D intakes varies by
country, depending on the combined effects of different fac-
tors, such as eating pattern, geographical location, available
solar UVB doses, pollution, and sun habits. A number of
national dietary surveys indicated a widespread prevalence
of suboptimal intakes for several micronutrients, including
vitamin D3 [94]. In particular, it has been demonstrated that
cholecalciferol (vitamin D3) is significantly more efficacious
than is ergocalciferol (vitamin D2) not only in increasing
serum 25(OH) D concentrations, but also for maintaining
serum vitamin D levels and its biological activities [95].
Whereby, vitamin D3 is the preferred choice for correcting
the low vitamin D status and maintenance with oral supple-
ments. The current evidence supports the hypothesis that
normal vitamin D status, 25-OH vitamin D above 30 ng/
mL (>75 nmol/L), improves the metabolic aspects, such as
obesity [96]. Only few foods contain vitamin D3 and several
studies suggest that we may need more vitamin D3 than
presently recommended to prevent chronic non-
transmissible diseases [97, 98]. In particular, vitamin D3 is
present in oil-rich fish, sunlight-exposed mushrooms, eggs,
and milk [3]. Cod liver oil is a rich natural source of vitamin
D3; nevertheless, there is concern regarding its use at high
doses due to its vitamin A content and the possible contam-
ination by heavy metals, such as mercury [99, 100]. The
Recommended Dietary Allowances (RDAs) covering re-
quirements of ≥97.5% of the population by life stage are
shown in Table 1.
The Mediterranean diet has been described as a healthy
eating pattern that promotes good health, a healthy body
weight, and disease prevention throughout the lifespan, due
to the proportion in which it includes all the food groups
(https://health.gov/dietaryguidelines/2015/) [101].
Nevertheless, in the last few years unfavourable changes in
the traditional Mediterranean lifestyle (reduction in outdoor
physyscal activity, clothing, smog, etc), could have induced
changes from the recommended intakes in relation to several
nutrients, making difficult to ensure adequate intakes of
vitamins and minerals. Accordingly, a recent review on the
available evidence on the Nutritional Adequacy of the
Mediterranean Diet has recently reported that a greater
adherence to the Mediterranean diet has been associated
with a higher prevalence of individuals showing adequate
intakes of micronutrients, including vitamin D3 [102].
However, according with the Authors of this study, there is
need to increase the knowledge on the nutritional adequacy of
the Mediterranean Diet as the first step towards the
introduction of correcting measures about the characteristics
of theMediterranean diet which are being lost or, alternatively,
should be restored.
Despite sensible exposure to sunlight remains the best,
cheapest and the safest way to obtain vitamin D3, food forti-
fication programs represent a logical approach to solve the
global epidemic of vi tamin D deficiency [103] .
Nevertheless, as it remains difficult to define the proportion
that should be obtained from the diet or from conversion
through the skin stimulated by UVexposure for each country,
it may be advantageous to have country-specific recommen-
dations for vitamin D.
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5 Supplementations of vitamin D in obese patients
5.1 Supplementations in obese patients
Some studies have reported that vitamin D supplementation
can also be beneficial for obese patients. In a double-blind,
randomized clinical trial, placebo-controlled in 77 healthy
overweight and obese women, vitamin D supplementation
(25 μg per day as cholecalciferol) after 12 weeks resulted in
a significant reduction in the body fat mass in women who
received vitamin D3 compared with those in the placebo
group [104]. The response to vitamin D supplementations
is dependent on body weight. A study demonstrated that
after supplementation, the increase in serum 25(OH)D3
levels was lower in overweight or obese women than in
women with normal BMI. In particular, the Authors reported
that normal weight women reached higher levels of serum
25(OH)D3 after vitamin D supplementation and suggested
that, as the dose response curves are parallel between normal
weight and obese people, the difference in serum 25(OH)D3
levels were probably due to a volume dilution effect; in
particular, after vitamin D supplementation in the over-
weight and obese groups 25(OH)D3 levels were 7 ng/mL
lower than in the group with BMI <25 kg/m2 [105]. Very
recently, Mason C. et al., reported that vitamin D supple-
mentation (2000 IU/day) in women with low vitamin D
status at baseline had no effect on body weight or fat loss
in postmenopausal women consuming a calorie-restricted
diet and following an exercise program [106].
As above mentioned, in obese subjects ∼2.5 IU/kg were
required for every unit increment in 25(OH)D3 ng/mL [29].
On this basis, in obese patients, higher doses (two to three
times higher; at least 6000–10,000 IU/d) of vitamin D3 are
necessary to treat vitamin D deficiency and to maintain
25(OH)D3 levels >30 ng/mL, followed by maintenance ther-
apy of 3000–6000 IU/d [9].
5.2 Vitamin D status and bariatric surgery
Considering the high risk for a low vitamin D status in obesity
related to the poor quality of the diet and low micronutrient
intake, a careful evaluation of vitamin D status as part of the
preoperative nutritional screening should be considered in all
bariatric surgery candidates in the preoperative setting due the
adjunctive impact of the malabsorption of vitamin D induced by
bariatric surgery [107]. Low vitamin D status is common in
bariatric patients [108], and often requires substantial supple-
mentation to achieve sufficiency [109]. While pure restrictive
procedures, such as laparoscopic adjustable gastric band
(LAGB), are not necessarily related to vitaminDmalabsorption,
a low vitamin D status can occur commonly after malabsorptive
interventions, including gastric bypass, biliopancreatic diversion
with duodenal switch, which preserves the duodenum, and
biliopancreatic diversion without duodenal switch, with a grow-
ing risk from the first to the last procedures [110]. Consequently,
after LAGB current recommendations of the Endocrine Society
Clinical Practice Guideline are a minimum of 600 IU/day of
vitamin D consistent with established age-specific recommen-
dations for patients at risk for vitamin D deficiency until non
obese [9]. After gastric bypass gastric bypass and other
malabsorptive, the low vitamin D status should be treated with
50.000 IU once a week for 8 weeks or 6000 IU/day of vitamin
D3, to achieve a blood level of 25(OH)D3 > 30 ng/ml, followed
by maintenance therapy of 1500–2000 IU/day. Severe deficien-
cies can be treated with doses up to 50.000 IU three times a day
or, rarely, with intramuscular injections of ergocalciferol
100.000 IU once a week [9, 111].
6 Conclusions
Several studies reported a positive association between low
vitamin D status and obesity, supporting the role for
Table 1 Vitamin D dietary
reference intakes by life stage Life-stage group RDA Serum 25OHD level
(intake that covers needs of ≥97.5% of population) (corresponding to the RDA)a
IU/d mcg/d ng/ml
Infants (0–12 months) 400b 10b 20
1–70 yr 600 15 20
+ 70 yr 800 20 20
Pregnant 600 15 20
Lactating 600 15 20
aMeasures of serum 25(OH)D3 levels corresponding to the RDA and covering the requirements of at least 97.5%
of the population
b Reflects adequate intake reference value rather than RDA. RDAs have not been established for infants
The Recommended Dietary Allowances (RDAs) by life stage
RDA Recommended dietary allowance, IU International unit
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supplementations of vitamin D in obese patients. Up to now
the nature of the bi-directional association between low vita-
min D status and obesity, the exact mechanisms responsible
for this association, and the clinical usefulness to increase
vitamin D status for reducing adiposity still warrant further
evaluation. In addition, it is not clear whether obesity plays a
causal role in the development of the low vitamin D status or,
alternatively, the low vitamin D status is involved in the de-
velopment of obesity. Residual confounding could exist from
factors, such as limited physical activity or low vitamin D3
intake. Indeed, the low vitamin D status is likely to contribute
per se to the development of overweight/obesity and different
genomic and non-genomic mechanisms exerted by vitamin
D3 have been proposed to have a causative role in obesity.
Hence, Nutritionists need to accurately address the aspects
influencing the low vitamin D status in obesity and the vita-
min D supplementation in obese individuals.
25(OH)D3, 25-hydroxyvitamin D3; BMI, body mass in-
dex; vitamin D3, cholecalciferol; 1α,25(OH)2D3, 1,25-
dihydroxyvitamin D3; PTH, Parathyroid Hormone; VDR,
Vitamin D Receptor; WC, Waist Circumference; BIA,
biompedeance analysis; VAT, Visceral Adipose Tissue, SAT,
Adipose Tissue Subcutaneously.
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